# SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

> **NCT05498636** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 67 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **COMBINATION_PRODUCT:** Selinexor combined with Prednisone, Etoposide, and Lenalidomide

## Key facts

- **NCT ID:** NCT05498636
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05498636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05498636, "SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05498636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*